Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CXCR6 | O00574 | 9/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13490329 | 1.00 | GRM5 (0.52) | GRM5MEN1KMT2ACXCR6LMNA | |
| SCHEMBL3222191 | 0.93 | GRM5 (0.52) | GRM5MEN1KMT2ACXCR6LMNA | |
| SCHEMBL3211354 | 0.90 | MEN1 (0.49) | GRM5MEN1KMT2ACXCR6LMNA | |
| SCHEMBL3199183 | 0.90 | MEN1 (0.49) | GRM5MEN1KMT2ACXCR6LMNA | |
| SCHEMBL3216538 | 0.89 | MEN1 (0.48) | GRM5MEN1KMT2ACXCR6LMNA | |
| SCHEMBL3209813 | 0.89 | MEN1 (0.48) | GRM5MEN1KMT2ACXCR6LMNA | |
| SCHEMBL3213601 | 0.88 | KMT2A (0.47) | GRM5MEN1KMT2ACXCR6LMNA | |
| SCHEMBL13490741 | 0.88 | MEN1 (0.54) | GRM5MEN1KMT2ACXCR6LMNA | |
| SCHEMBL13490372 | 0.88 | MEN1 (0.54) | GRM5MEN1KMT2ACXCR6LMNA | |
| SCHEMBL13490618 | 0.88 | MEN1 (0.54) | GRM5MEN1KMT2ACXCR6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2010-02-04 | — | — | US | claimed |
| EP-2121626-A1 | BENZIMIDAZOLE DERIVATIVES | Pfizer Products Inc. (US) | 2009-11-25 | — | — | EP | claimed |
| WO-2008075196-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | claimed |
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2010-02-04 | — | — | US | disclosed |
| EP-2121626-A1 | BENZIMIDAZOLE DERIVATIVES | Pfizer Products Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008075196-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | ACIN1, HAT1, CCNE1 | GRM5 4172/4885MEN1 2892/4885KMT2A 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.